Mdd Clinical Trials 2023

What are the top hospitals conducting mdd research?

When it comes to advancing the treatment options for Major Depressive Disorder (MDD), several hospitals are making significant contributions through their clinical trials. In Orlando, APG Research, LLC is at the forefront with four active MDD trials and a total of five completed trials since they started their pioneering research in 2018. Similarly, Baber Research Group in Naperville has been instrumental in the field, currently conducting four ongoing MDD trials while having accomplished nine previous studies since initiating their first trial back in 2012.

Moving on to Gainesville, Sarkis Clinical Trials continues to play a crucial role with four active MDD trials and an impressive history of twenty-two completed studies since recording their first trial in 2004. Meanwhile, at the National Institutes of Health Clinical Center in Bethesda—a renowned medical institution—researchers are also dedicatedly working towards advancements in MDD treatment. They have developed four active clinical trials for this condition and have completed nine previous studies after starting their initial trial back in 2001.

Lastly, Proscience Research Group based out of Culver City may be relatively new to the scene but has wasted no time contributing to MDD research. With three ongoing clinical trials focused on this mental health disorder and already completing three others since recording their first trial just last year (2020), they are quickly establishing themselves as a prominent player within the medical community.

These hospitals' commitment to finding innovative ways to treat Major Depressive Disorder is inspiring not only for patients who suffer from this condition but also for healthcare professionals worldwide seeking effective solutions. Through these collaborative efforts between researchers and participants alike, there is hope that breakthroughs will continue to emerge leading us towards improved treatments and ultimately better outcomes for individuals grappling with MDD.

Which are the best cities for mdd clinical trials?

Miami, Florida; New york, New York; Orlando, Florida; San Diego, California; and Houston, Texas are the top cities for major depressive disorder (MDD) clinical trials. Miami leads with 26 active trials investigating treatments like Aticaprant, REL-1017, and Seltorexant. Following closely behind is New York with 18 ongoing studies focusing on similar interventions. Orlando has 16 active trials exploring options such as Seltorexant and TNX-601 ER. Meanwhile, both San Diego and Houston offer 14 active MDD trials each that include investigational drugs like Lumateperone and Esketamine. These cities serve as hubs of research to advance our understanding of MDD treatment options and potentially improve patient outcomes.

Which are the top treatments for mdd being explored in clinical trials?

Exciting developments are underway in the realm of MDD treatments, with several interventions taking center stage in clinical trials. Leading the charge is psilocybin, a substance being tested in five active trials for MDD. Since its initial listing in 2017, it has accumulated an impressive portfolio of 13 all-time trials focused on this condition. Another promising contender is aticaprant, currently involved in three ongoing trials and making waves since its introduction in 2022. Also showing potential are seltorexant and lumateperone, both engaged in three active MDD studies since their debut on the scene back in 2020. Rounding out the top treatments is left dorsolateral prefrontal cortex (L-DLPFC), which shows promise despite having only two active trials to date. As researchers continue to delve deeper into these innovative therapies, hope grows brighter for individuals battling MDD around the world.

What are the most recent clinical trials for mdd?

Exciting advancements are being made in the field of Major Depressive Disorder (MDD) research, with recent clinical trials exploring new treatment options. One such trial focuses on esketamine, a medication that has shown promise in treating MDD. Another study investigates the use of ketamine combined with perampanel as a potential therapy for individuals with MDD. Additionally, researchers are studying the effects of high CBD [25:1] and REL-1017 25 mg on patients diagnosed with MDD. Lastly, omega-3 supplementation is being explored as a possible adjunctive treatment for individuals living with this debilitating condition. These innovative trials offer hope to those affected by MDD and signify significant progress towards improving outcomes in its management.

What mdd clinical trials were recently completed?

Several notable clinical trials for major depressive disorder (MDD) have recently concluded, showcasing advancements in treatment options. In June 2022, Alto Neuroscience successfully completed a trial evaluating the ALTO-100 PO Tablet's efficacy. Furthermore, Alto Neuroscience concluded two more trials involving the ALTO-100 and ALTO-300 PO tablets in December 2021. Other noteworthy completed trials include Neurocrine Biosciences' study on NBI-1065846 in November 2021 and Cerevel Therapeutics' investigation of CVL-354 in October 2021. These recent milestones highlight ongoing efforts to address MDD through innovative therapeutic approaches, providing hope for individuals grappling with this challenging condition.